Starling Oncology, Inc.
STLN
Positions held
Your positionsSTLN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $629.84M | Enterprise value | $693.54M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | -24.92 | Beta | 0.42 | Dividend yield | 0.00% |
| Revenue growth | 34.6% | Earnings growth | — | Gross margin | 15.7% | Operating margin | -2.9% |
| Profit margin | -6.2% | ROE | — | ROA | -9.6% | Debt / equity | — |
| Current ratio | 1.36 | Free cash flow | $8.60M | Analyst recommendation | strong_buy | Mean target | $9.00 |
| 52w high | $7.13 | 52w low | $2.32 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $161M | $147M | $142M | $137M | $120M |
| Op margin | -2.9% | -4.4% | -4.9% | -5.9% | -9.4% |
| Net income | -$9.8M | -$2.5M | -$7.5M | -$16.5M | -$17.0M |
| Gross margin | 16.8% | 15.8% | 16.0% | 13.9% | 14.6% |
| Gross profit | $27.2M | $23.3M | $22.8M | $18.9M | $17.5M |
| Operating income | -$4.6M | -$6.5M | -$6.9M | -$8.1M | -$11.2M |
- Revenue +9% vs prior quarter ($161M vs $147M).
- Gross margin 16.8% (was 15.8% prior quarter).
- Operating margin expanded to -2.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $503M | $393M | $324M | $252M | — |
| Op margin | -7.2% | -15.3% | -18.6% | -28.5% | — |
| Net income | -$60.6M | -$64.7M | -$83.1M | $0.2M | — |
| Gross margin | 15.2% | 13.7% | 18.4% | 20.6% | — |
| Gross profit | $76.4M | $54.0M | $59.6M | $52.1M | — |
| Operating income | -$36.1M | -$60.1M | -$60.2M | -$72.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
2026-08-24 · Starling Oncology to Participate in Wells Fargo Healthcare Conference
2026-08-07 · Oncology Institute Q2 Earnings Call Highlights
2026-08-06 · The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates
2026-08-06 · Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
2026-08-06 · Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
2026-08-05 · Earnings To Watch: Starling Oncology Inc (STLN) Q2 2026 -- GF Value Sees 44% Downside
Price (daily)
Full chart · RSI · MACD · patterns